Prenatal exposure to serotonin reuptake inhibitors and congenital heart anomalies: an exploratory pharmacogenetics study.
Pharmacogenomics
; 18(10): 987-1001, 2017 Jul.
Article
en En
| MEDLINE
| ID: mdl-28639488
ABSTRACT
AIM:
To explore the role of pharmacogenetics in determining the risk of congenital heart anomalies (CHA) with prenatal use of serotonin reuptake inhibitors.METHODS:
We included 33 case-mother dyads and 2 mother-only (child deceased) cases of CHA in a case-only study. Ten genes important in determining fetal exposure to serotonin reuptake inhibitors were examined CYP1A2, CYP2C9, CYP2C19, CYP2D6, ABCB1, SLC6A4, HTR1A, HTR1B, HTR2A and HTR3B.RESULTS:
Among the exposed cases, polymorphisms that tended to be associated with an increased risk of CHA were SLC6A4 5-HTTLPR and 5-HTTVNTR, HTR1A rs1364043, HTR1B rs6296 and rs6298 and HTR3B rs1176744, but none reached statistical significance due to our limited sample sizes.CONCLUSION:
We identified several polymorphisms that might potentially affect the risk of CHA among exposed fetuses, which warrants further investigation.Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Efectos Tardíos de la Exposición Prenatal
/
Inhibidores Selectivos de la Recaptación de Serotonina
/
Exposición Materna
/
Polimorfismo de Nucleótido Simple
/
Variantes Farmacogenómicas
/
Cardiopatías Congénitas
Límite:
Female
/
Humans
/
Male
/
Newborn
/
Pregnancy
Idioma:
En
Revista:
Pharmacogenomics
Asunto de la revista:
FARMACOLOGIA
/
GENETICA MEDICA
Año:
2017
Tipo del documento:
Article
País de afiliación:
Países Bajos